LONP1: A Promising Protein Target for Therapeutic Agents (G9361)

Target Name: LONP1

NCBI ID: G9361

LONP1

LONP1: A Promising Protein Target for Therapeutic Agents

LONP1 (LONM_HUMAN), also known as human long non-protein tail-modified peptide-1, is a protein that is expressed in a variety of human tissues and has been shown to play a role in a number of cellular processes. Several studies have LONP1 was identified as a potential drug target or biomarker, and research is ongoing to determine its potential utility as a therapeutic agent.

The LONP1 protein is characterized by its unique structure, which consists of a long non-protein peptide-1 (LONP1) domain and a C-terminus that is rich in conserved amino acid sequence. LONP1 is expressed in a variety of human tissues, including muscle, pancreas, and brain, and has been shown to play a role in a number of cellular processes.

One of the key features of LONP1 is its ability to interact with a variety of protein partners, including other long non-protein tail-modified peptides (LONP2s) and the protein PDGF-BB. These interactions can modulate the activity and structure of LONP1 and potentially influence a wide range of cellular processes.

In addition to its potential as a drug target, LONP1 has also been identified as a potential biomarker for a number of diseases. For example, studies have shown that LONP1 is expressed in the pancreatic cancer, and that high expression of LONP1 is associated with poor prognosis in pancreatic cancer patients. Additionally, LONP1 has been shown to be expressed in the brain, and that its expression is associated with a number of neurological diseases, including Alzheimer's disease and Parkinson's disease.

While more research is needed to fully understand the potential utility of LONP1 as a drug or biomarker, it is clear that LONP1 is a promising target for future research. Researchers are currently working to develop small molecules that can specifically interact with LONP1 and modulate its activity , with the goal of using these compounds as therapeutic agents for a variety of diseases.

In conclusion, LONP1 is a protein that has been identified as a potential drug target and biomarker. Its unique structure and ability to interact with a variety of protein partners make it an attractive target for small molecule therapy. While more research is needed to fully understand the potential utility of LONP1, it is clear that LONP1 is a promising target for future research.

Protein Name: Lon Peptidase 1, Mitochondrial

Functions: ATP-dependent serine protease that mediates the selective degradation of misfolded, unassembled or oxidatively damaged polypeptides as well as certain short-lived regulatory proteins in the mitochondrial matrix. May also have a chaperone function in the assembly of inner membrane protein complexes. Participates in the regulation of mitochondrial gene expression and in the maintenance of the integrity of the mitochondrial genome. Binds to mitochondrial promoters and RNA in a single-stranded, site-specific, and strand-specific manner. May regulate mitochondrial DNA replication and/or gene expression using site-specific, single-stranded DNA binding to target the degradation of regulatory proteins binding to adjacent sites in mitochondrial promoters (PubMed:12198491, PubMed:15870080, PubMed:17420247, PubMed:8248235). Endogenous substrates include mitochondrial steroidogenic acute regulatory (StAR) protein, helicase Twinkle (TWNK) and the large ribosomal subunit protein bL32m. bL32m is protected from degradation by LONP1 when it is bound to a nucleic acid (RNA), but TWNK is not (PubMed:17579211, PubMed:28377575)

The "LONP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LONP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets